Featured Research

from universities, journals, and other organizations

Protein Level Predicts Who Will Develop Deadly Complication After Marrow Transplant

Date:
February 18, 2006
Source:
University of Michigan Health System
Summary:
Researchers could determine one week after a bone marrow transplant which patients were likely to develop a serious and deadly complication, making them candidates for preventive treatment before any symptoms occur.

Researchers could determine one week after a bone marrow transplant which patients were likely to develop a serious and deadly complication, making them candidates for preventive treatment before any symptoms occur.

Researchers at the University of Michigan Comprehensive Cancer Center measured the level of a protein called tumor necrosis factor, or TNF, seven days after patients received a bone marrow transplant. TNF, a trigger for inflammation, is known to be elevated in people who develop graft vs. host disease, the most common serious side effect of a bone marrow transplant from a donor.

Bone marrow transplant is a lifesaving treatment given to children or adults with certain types of cancer, such as leukemia or lymphoma, or to people with some blood or immune disorders. A transplant allows higher doses of chemotherapy to be used to destroy cancer, because the damaged bone marrow is replaced by the transplanted healthy marrow. But the complicated treatment carries a risk of the body rejecting the new bone marrow, a condition called graft vs. host disease, or GVHD. The transplanted immune cells can attack the patient's skin, liver and gastrointestinal cells, triggering a massive inflammatory reaction that can kill the patient.

The study looked at 170 patients, 94 of whom went on to develop graft vs. host disease, a condition in which the transplanted immune system attacks the patient's normal tissue. Those 94 patients had elevated levels of the TNF-receptor protein a week after their transplant -- before they showed any symptoms of graft vs. host disease. Researchers also found patients whose TNF level was elevated at seven days had a 20-point lower survival rate: 62 percent were alive after a year, compared to 85 percent of those with a lower TNF.

"This suggests we could target patients to prevent graft vs. host disease based on their post-transplant level of TNF. If we can develop a test that can reliably predict this complication, we can then look at treating it before any symptoms develop. This is one small step in a long road to making transplants safer and more effective," says study author John Levine, M.D., associate professor of pediatrics and internal medicine at the U-M Medical School.

Levine will present these findings Friday, Feb. 17, 2006, at the American Society for Blood and Marrow Transplant annual meeting.

Research led by James Ferrara, M.D., director of the Blood and Marrow Transplantation Program at the U-M Comprehensive Cancer Center has previously linked TNF to graft vs. host disease.

"TNF is known to play a role in a variety of inflammatory or autoimmune diseases, including septic shock, rheumatoid arthritis and Crohn's disease. Anti-TNF drugs are already FDA-approved and available on the market. We are currently conducting a clinical trial using one of these drugs, etanercept, in clinical trials to see if it can prevent or treat GVHD," says study author Carrie Kitko, M.D., a pediatric fellow at the U-M Health System.

About 40 percent to 50 percent of all patients who receive a bone marrow transplant will develop GVHD, and 30 percent will die from this complication. The U-M Comprehensive Cancer Center performs 250 blood and marrow transplants each year, in both children and adults. For more information, visit www.cancer.med.umich.edu/clinic/bmtclinic.htm or call the Cancer AnswerLine at 800-865-1125.

###

The research was funded by a Doris Duke Charitable Foundation Distinguished Clinical Scientist Award.

Reference: American Society for Blood and Marrow Transplant annual meeting, Feb. 17, 2006, Honolulu, Hawaii.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Protein Level Predicts Who Will Develop Deadly Complication After Marrow Transplant." ScienceDaily. ScienceDaily, 18 February 2006. <www.sciencedaily.com/releases/2006/02/060217092148.htm>.
University of Michigan Health System. (2006, February 18). Protein Level Predicts Who Will Develop Deadly Complication After Marrow Transplant. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2006/02/060217092148.htm
University of Michigan Health System. "Protein Level Predicts Who Will Develop Deadly Complication After Marrow Transplant." ScienceDaily. www.sciencedaily.com/releases/2006/02/060217092148.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins